INDOCO REMEDIES DRUG VACCINE FOR COVID19 PATIENTS | SURYA ROSHNI SHARES GONE 10 PERCENT | 2020

 INDOCO REMEDIES DRUG VACCINE FOR COVID19 PATIENTS 

Domestic stock markets are showing aggression for the second day in a row on the back of global markets. Currently, the Sensex is up 483 points at 37,872. Demand for this specialty has grown significantly as a result of the launch of Favipiravir, a drug used in the treatment of Covid-19. On the other hand, Surya Roshni Counter, a steel and electrical lighting products company, is also impressing investors with its recent orders from PSU giants. Versace Both of these counters are intertwined with huge profits. Let's see the details.

INDOCO REMEDIES:-

Pharma-based pharmaceutical company Indocoremides has revealed that Favipiravir has been launched in the domestic market in 400 mg dosage under the name Favindo 400. The RGA-based drug has been approved by the DCGI for the construction of the influenza virus. 

In addition to this drug, Indoco has also released Povidone-Loading Gargil, which can be used as part of COVID-19 treatment, and tablets that can boost immunity. Revealed that these tablets contain zinc, vitamin v, d. Against this backdrop, Indoco shares initially surged 9% on the NSE. Rs. Hit an intraday high at 284. At present, 5 percent of Egasi is worth Rs. Trading at 275.

SURYA ROSHNI:- 

Oil and Gas PSUs from GAIL, IGGL for Rs. Surya Roshni said contracts worth Rs 273 crore were recently awarded. As part of the orders, API Line will supply the pipes to GAIL and IGGL (Rainbow Gas Grid). The orders were received as part of the Northeast Gas Grid Project. Against this backdrop, Surya Roshni shares initially jumped 10 percent on the NSE. Rs. Touched 213. This is a 52-week high. At present, it is trading at Rs. Trading at 206.